Author’s Reply to Petersen: “Differences in In Vitro Properties of Pancreatin Preparations for Pancreatic Exocrine Insufficiency as Marketed in Russia and CIS”-Reference-Cited by-同舟云学术

Author’s Reply to Petersen: “Differences in In Vitro Properties of Pancreatin Preparations for Pancreatic Exocrine Insufficiency as Marketed in Russia and CIS”

Published:2021-10-23 Issue:4 Volume:21 Page:469-470
ISSN:1174-5886
Container-title:Drugs in R&D
language:en
Short-container-title:Drugs R D

Author:

Maev Igor V.,Kucheryavyy Yury A.,Gubergrits Natalya B.,Bonnacker Ingo,Shelest Ekaterina A.,Janssen‑van Solingen Gwendolyn P.^ORCID,Dominguez‑Munoz J. Enrique

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40268-021-00364-1.pdf

Reference4 articles.

1. Petersen KU. Comment on: "Differences in in vitro properties of pancreatin preparations for pancreatic exocrine insufficiency as marketed in Russia and CIS". Drugs RD. https://doi.org/10.1007/s40268-021-00366-z

2. Maev IV, Kucheryavyy YA, Gubergrits NB, Bonnacker I, Shelest EA, Janssen-van Solingen GP, et al. Differences in in vitro properties of pancreatin preparations for pancreatic exocrine insufficiency as marketed in Russia and CIS. Drugs RD. 2020;20:369–76. https://doi.org/10.1007/s40268-020-00326-z.

3. Löhr JM, Domínguez-Muñoz JE, Rosendahl J, Besselink M, Mayerle J, Lerch MM, et al. United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU). United Eur Gastroenterol J. 2017;5:153–99. https://doi.org/10.1177/2050640616684695.

4. Petersen K-U, Malfertheiner P, Mössner J. The role of sphere size in the context of pancreatin therapy for exocrine pancreatic insufficiency: a systematic review. J Gastrointest Liver Dis. 2021;30(1):132–41. https://doi.org/10.15403/jgld-2985.